nimodipine has been researched along with Central Nervous System Origin Vertigo in 8 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included." | 9.17 | Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo. ( Alejandro, R; Carlos, RJ; Consuelo, P; Elena, C; Glenda, C; Lisbeth, M; Maria, GY, 2013) |
| "There were two formulations used to assess the effectiveness in vertigo treatment from peripheral origin: nimodipine administrated three times daily (Nimotop®) 30 mg versus nimodipine AP administrated once daily (Tropocer®) 90 mg; both of them in a administrated in a prospective, randomized, double-blind, double dummy, multicenter and parallel-group study, where patients with peripheral vertigo defined as a score ≥7 on the Vertigo-Dizziness Differential Diagnosis Score were included." | 5.17 | Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo. ( Alejandro, R; Carlos, RJ; Consuelo, P; Elena, C; Glenda, C; Lisbeth, M; Maria, GY, 2013) |
| "Eighty-three patients with CCI were randomly divided into YXQNG and nimodipine (ND) groups, the score of vertigo and the change in cerebral blood velocity before and after treatment were observed." | 5.11 | Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency. ( Cai, DF; Chen, YP; Gu, XX; Teng, Y; Wen, M; Yang, YK, 2005) |
| "Two calcium antagonists were used to treat vertigo (nimodipine, 89 patients; cinnarizine, 92 patients), and all patients were maintained on the same dosage regimen until they completed 12 weeks of treatment." | 5.10 | New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study. ( Abiuso, J; Alegría, J; Arenas, JE; Castañeda, JR; F, GV; Flaskamp, R; Gómez, JM; González, RH; Guerra, OJ; Hanuch, E; Hernández, J; Hidalgo, LO; Madrid, CE; Martínez, C; Morán, LM; Pedraza, A; Pianese, CP; Ponce, JE; Quijano, D; Ramírez, AM; Rubio, AT; Sanjuán, AP; Uribe, JO; Volpi, C, 2002) |
| "Due to its proposed vasoactive and neuroprotective effects, nimodipine may play a role in the treatment of a number of otolaryngic pathologies including VS, Ménière's disease, peripheral vertigo, RLN injury, and facial weakness after maxillofacial surgery." | 4.98 | Nimodipine for the treatment of otolaryngic indications. ( Levy, ZD; Shafeeq, H; Sin, JH, 2018) |
| "An animal experimental model of vertebrobasilar insufficiency was developed." | 2.66 | Calcium entry blockers in the treatment of vertebrobasilar insufficiency. ( Hofferberth, B, 1986) |
| "Vertebrobasilar insufficiency (VBI) is a clinical syndrome which includes different transient brain stem symptoms." | 2.65 | [Calcium blockers in the therapy of vertebrobasilar insufficiency. Results of animal experiments and clinical studies]. ( Hofferberth, B, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sin, JH | 1 |
| Shafeeq, H | 1 |
| Levy, ZD | 1 |
| Wu, C | 1 |
| Liao, L | 1 |
| Yan, X | 1 |
| Li, M | 1 |
| Wu, S | 1 |
| Wang, J | 1 |
| Lin, J | 1 |
| Li, S | 1 |
| Gao, L | 1 |
| DU, J | 1 |
| Yang, R | 1 |
| Lisbeth, M | 1 |
| Consuelo, P | 1 |
| Glenda, C | 1 |
| Elena, C | 1 |
| Carlos, RJ | 1 |
| Alejandro, R | 1 |
| Maria, GY | 1 |
| Monzani, D | 1 |
| Genovese, E | 1 |
| Pini, LA | 1 |
| Di Berardino, F | 1 |
| Alicandri Ciufelli, M | 1 |
| Galeazzi, GM | 1 |
| Presutti, L | 1 |
| Gu, XX | 1 |
| Cai, DF | 1 |
| Yang, YK | 1 |
| Teng, Y | 1 |
| Chen, YP | 1 |
| Wen, M | 1 |
| Hofferberth, B | 2 |
| Pianese, CP | 1 |
| Hidalgo, LO | 1 |
| González, RH | 1 |
| Madrid, CE | 1 |
| Ponce, JE | 1 |
| Ramírez, AM | 1 |
| Morán, LM | 1 |
| Arenas, JE | 1 |
| Rubio, AT | 1 |
| Uribe, JO | 1 |
| Abiuso, J | 1 |
| Hanuch, E | 1 |
| Alegría, J | 1 |
| Volpi, C | 1 |
| Flaskamp, R | 1 |
| Sanjuán, AP | 1 |
| Gómez, JM | 1 |
| Hernández, J | 1 |
| Pedraza, A | 1 |
| Quijano, D | 1 |
| Martínez, C | 1 |
| Castañeda, JR | 1 |
| Guerra, OJ | 1 |
| F, GV | 1 |
2 reviews available for nimodipine and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Nimodipine for the treatment of otolaryngic indications.
Topics: Calcium Channel Blockers; Humans; Meniere Disease; Neuroprotective Agents; Nimodipine; Otorhinolaryn | 2018 |
Nimodipine in otolaryngology: from past evidence to clinical perspectives.
Topics: Calcium Channel Blockers; Humans; Migraine Disorders; Nimodipine; Otorhinolaryngologic Diseases; Ver | 2015 |
6 trials available for nimodipine and Central Nervous System Origin Vertigo
| Article | Year |
|---|---|
Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: a randomized, double-blind, double-dummy, controlled multicentre trial.
Topics: Adult; Cerebrovascular Circulation; China; Dizziness; Dose-Response Relationship, Drug; Double-Blind | 2013 |
Evaluation of the effect of nimodipine o.d. (extended release) vs nimodipine t.i.d. in the treatment of peripheral vertigo.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind | 2013 |
Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency.
Topics: Aged; Aged, 80 and over; Animals; Blood Flow Velocity; Cerebrovascular Circulation; Cerebrovascular | 2005 |
[Calcium blockers in the therapy of vertebrobasilar insufficiency. Results of animal experiments and clinical studies].
Topics: Animals; Calcium Channel Blockers; Cerebrovascular Circulation; Cinnarizine; Clinical Trials as Topi | 1984 |
New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cinnarizine; Drug Administration Schedule; | 2002 |
Calcium entry blockers in the treatment of vertebrobasilar insufficiency.
Topics: Animals; Clinical Trials as Topic; Dogs; Flunarizine; Humans; Nimodipine; Nystagmus, Pathologic; Pen | 1986 |